AEMD
Aethlon Medical, Inc. (AEMD) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No reported 5-year revenue CAGR limits evidence of durable top-line compounding, while peers with disclosed multi-year growth can demonstrate clearer scaling trajectories.
Near-zero capex-to-revenue suggests limited reinvestment into capacity expansion, reducing the company’s ability to translate demand into sustained revenue growth versus peers.
Negative ROIC indicates capital deployed has not yet generated scalable returns, which weakens the case for self-funded expansion relative to profitable peers.
Extremely weak cash conversion metrics imply growth, if any, is not being converted into durable internal funding, constraining repeatable revenue expansion versus stronger peers.
Market Tailwinds
No disclosed segment concentration or market-share data prevents evidence of a differentiated demand engine, leaving growth visibility weaker than peers with measurable share gains.
The company’s financial profile does not show a proven, recurring expansion vector, whereas peers with stronger operating leverage can compound revenue more predictably.
Negative profitability and cash generation suggest any market opportunity is not yet being captured at scale, limiting the durability of external demand tailwinds.
Without documented multi-year growth metrics, the business appears less supported by structural tailwinds than peers with established recurring demand.
Scalability Expansion
Negative ROIC and negative interest coverage indicate expansion is not currently supported by scalable economics, unlike peers that can reinvest from operating surplus.
The absence of positive free-cash-flow evidence reduces internal funding for commercialization, making multi-year scaling more dependent on external capital than peers.
Very weak cash conversion implies operational scaling is not translating into cash, which limits compounding capacity and raises execution friction versus stronger peers.
Low capex intensity may preserve cash, but it also signals limited capacity-building investment, capping long-term expansion potential relative to more scalable peers.
Constraints Limitations
Negative interest coverage and weak profitability create financing constraints that can restrict growth duration, especially versus peers with self-funding balance sheets.
The lack of verified historical growth metrics makes it difficult to evidence repeatable scaling, which structurally lowers confidence in long-term compounding versus peers.
Poor cash conversion and negative ROIC indicate that incremental activity has not yet produced durable economic expansion, limiting reinvestment capacity.
Minimal capital deployment may reduce burn, but it also suggests a constrained operating model that has not demonstrated scalable revenue creation.
Overall Score
AEMD shows limited evidence of durable, self-funded revenue compounding, and its negative profitability, weak cash conversion, and financing constraints place it well below scalable peers.
Score Driver: Negative Profitability
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Aethlon Medical, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
